首页 > 最新文献

Journal of the American Pharmacists Association最新文献

英文 中文
Pharmacy HIV pre-exposure prophylaxis/post-exposure prophylaxis furnishing: The benefits of collaborating with peer navigators 药房HIV PrEP/PEP提供:与同行导航合作的好处。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 DOI: 10.1016/j.japh.2025.102978
Alicia Morehead-Gee, Dino Selders, Kalaya Hill, Alejandro Chavez, Johanna Gonzalez, Lindsey Takata, Jacqueline Nazarian, David Mosqueda

Background

California Senate Bill 159 (2019) enables pharmacists to furnish oral human immunodeficiency virus pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) without a clinician's prescription; however, its implementation has been limited by barriers including time and space constraints. Noting these barriers, a peer navigator-led pharmacy PrEP/PEP program was created within a Southern California Federally Qualified Health Center (FQHC).

Objective

The program aimed to enable pharmacist PrEP/PEP furnishing through collaboration with navigators and increase the FQHC's number of PrEP patients by 25% in 2 years.

Methods

In 2021, a multidisciplinary team developed a program that involved navigators meeting with patients, conducting eligibility assessments, and providing human immunodeficiency virus testing to facilitate pharmacists' PrEP/PEP furnishing. From 2021 to 2023, the team implemented the program at 11 FQHC pharmacies by providing SB-159-required online trainings followed by in-person simulation trainings, allowing pharmacists to practice the workflow with navigators. This study evaluates the program using components of the RE-AIM framework, assessing the program's reach (number/type of encounters and demographics of program users) and efficacy (percentage of encounters that led to follow-up PrEP/PEP clinic visits) in its first 2 years.

Results

The pharmacy program had 238 total encounters within its first 2 years; 161 (67.6%) were for PrEP and 77 (32.4%) were for PEP. Of the 216 unique program users, 166 (76.9%) were documented as having Hispanic/Latinx ethnicity, and 145 (67.1%) were documented as LGBTQ+. Encounters led to 195 (81.9%) follow-up appointments scheduled, of which 156 (80.0%) were attended. The FQHC's number of enrolled PrEP patients increased from 239 in January 2022 to 339 in December 2023 (41.8%).

Conclusion

This pharmacy program successfully increased PrEP/PEP access by creating a collaborative workflow led by peer navigators. Navigators are key to facilitating PrEP/PEP furnishing by aiding pharmacists in completing requirements and offering individuals a nonjudgmental peer encounter to obtain PrEP/PEP.
背景:加州参议院法案159(2019)允许药剂师在没有临床医生处方的情况下提供口服HIV暴露前预防(PrEP)和暴露后预防(PEP);但是,它的实施受到时间和空间限制等障碍的限制。注意到这些障碍,在南加州联邦合格健康中心(FQHC)内创建了一个同行导航员领导的药房PrEP/PEP项目。目的:该项目旨在通过与导航员的合作,使药剂师能够提供PrEP/PEP,并在2年内将FQHC的PrEP患者数量增加25%。方法:2021年,一个多学科团队开发了一个项目,包括导航员与患者会面,进行资格评估并提供艾滋病毒检测,以促进药剂师提供PrEP/PEP。从2021年到2023年,该团队在11家FQHC药房实施了该计划,通过提供sb -159要求的在线培训,然后进行现场模拟培训,使药剂师能够与导航员一起练习工作流程。本研究使用RE-AIM框架的组件来评估该计划,评估该计划在头两年的覆盖范围(接触的数量/类型和计划用户的人口统计数据)和功效(接触导致后续PrEP/PEP诊所就诊的百分比)。结果:药学项目在前两年共接触238次;PrEP 161例(67.6%),PEP 77例(32.4%)。在216名独特的项目用户中,166名(76.9%)被记录为西班牙裔/拉丁裔,145名(67.1%)被记录为LGBTQ+。随访预约195次(81.9%),其中156次(80.0%)就诊。FQHC纳入的PrEP患者数量从2022年1月的239人增加到2023年12月的339人(41.8%)。结论:该药房项目通过创建由同行导航员领导的协作工作流程,成功地增加了PrEP/PEP的访问。导航员是促进PrEP/PEP提供的关键,他们帮助药剂师完成要求,并为个人提供获得PrEP/PEP的非评判性同伴接触。
{"title":"Pharmacy HIV pre-exposure prophylaxis/post-exposure prophylaxis furnishing: The benefits of collaborating with peer navigators","authors":"Alicia Morehead-Gee,&nbsp;Dino Selders,&nbsp;Kalaya Hill,&nbsp;Alejandro Chavez,&nbsp;Johanna Gonzalez,&nbsp;Lindsey Takata,&nbsp;Jacqueline Nazarian,&nbsp;David Mosqueda","doi":"10.1016/j.japh.2025.102978","DOIUrl":"10.1016/j.japh.2025.102978","url":null,"abstract":"<div><h3>Background</h3><div>California Senate Bill 159 (2019) enables pharmacists to furnish oral human immunodeficiency virus pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) without a clinician's prescription; however, its implementation has been limited by barriers including time and space constraints. Noting these barriers, a peer navigator-led pharmacy PrEP/PEP program was created within a Southern California Federally Qualified Health Center (FQHC).</div></div><div><h3>Objective</h3><div>The program aimed to enable pharmacist PrEP/PEP furnishing through collaboration with navigators and increase the FQHC's number of PrEP patients by 25% in 2 years.</div></div><div><h3>Methods</h3><div>In 2021, a multidisciplinary team developed a program that involved navigators meeting with patients, conducting eligibility assessments, and providing human immunodeficiency virus testing to facilitate pharmacists' PrEP/PEP furnishing. From 2021 to 2023, the team implemented the program at 11 FQHC pharmacies by providing SB-159-required online trainings followed by in-person simulation trainings, allowing pharmacists to practice the workflow with navigators. This study evaluates the program using components of the RE-AIM framework, assessing the program's reach (number/type of encounters and demographics of program users) and efficacy (percentage of encounters that led to follow-up PrEP/PEP clinic visits) in its first 2 years.</div></div><div><h3>Results</h3><div>The pharmacy program had 238 total encounters within its first 2 years; 161 (67.6%) were for PrEP and 77 (32.4%) were for PEP. Of the 216 unique program users, 166 (76.9%) were documented as having Hispanic/Latinx ethnicity, and 145 (67.1%) were documented as LGBTQ+. Encounters led to 195 (81.9%) follow-up appointments scheduled, of which 156 (80.0%) were attended. The FQHC's number of enrolled PrEP patients increased from 239 in January 2022 to 339 in December 2023 (41.8%).</div></div><div><h3>Conclusion</h3><div>This pharmacy program successfully increased PrEP/PEP access by creating a collaborative workflow led by peer navigators. Navigators are key to facilitating PrEP/PEP furnishing by aiding pharmacists in completing requirements and offering individuals a nonjudgmental peer encounter to obtain PrEP/PEP.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102978"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to “GLP-1 receptor agonists and diabetic retinopathy: Comment on a case report” 对“GLP-1受体激动剂与糖尿病视网膜病变:附一例报告”的反应。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 DOI: 10.1016/j.japh.2025.103000
Jennifer Ko PharmD, MPH, BCACP, APh, Yaseman Jahromi
{"title":"Response to “GLP-1 receptor agonists and diabetic retinopathy: Comment on a case report”","authors":"Jennifer Ko PharmD, MPH, BCACP, APh,&nbsp;Yaseman Jahromi","doi":"10.1016/j.japh.2025.103000","DOIUrl":"10.1016/j.japh.2025.103000","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 103000"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 2","pages":"Article 103011"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146480467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102935"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146629542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102914"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146629548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102936"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146629554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 103002"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146629566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102952"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146629576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102986"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146629610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practices and implementation factors of point-of-care testing for acute upper respiratory tract infections by community pharmacists in Alberta: A cross-sectional survey 艾伯塔省社区药剂师对急性上呼吸道感染的即时检测的实践和实施因素:一项横断面调查。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 DOI: 10.1016/j.japh.2025.102927
Omar E. Abdellatife, Scot H. Simpson, Theresa J. Schindel, Jody Shkrobot, Mark J. Makowsky

Background

Community pharmacists in Alberta have a broad scope of practice and may conduct point-of-care (POC) tests for acute and chronic medical conditions. However, little is known about the provision and pharmacists' experiences in POC testing for respiratory infections.

Objectives

To explore the clinical services offered by community pharmacist to patients with acute upper respiratory tract infections (URTI) by describing the types of POC tests performed and differences in implementation factors and confidence between active and inactive URTI POC testing providers.

Methods

Anonymous, online, cross-sectional survey with email invitations sent to 4035 community pharmacists registered with the Alberta College of Pharmacy in February 2024. The survey collected information on demographics and provision of POC testing services. An adapted version of the Determinants of Implementation Behavior Questionnaire (DIBQ) was used to determine barriers and facilitators. The data were summarized descriptively and compared between groups using univariate statistical tests.

Results

A total of 370 responses were included in the final analysis (response rate: 9.2%, 45% < 40 years old, 65% female, 28% rural, 73% have additional prescribing authorization). Most respondents (87%) provide assessments to patients presenting with URTI symptoms. Three quarters (72.7%) provide POC testing, 65% currently provide URTI POC tests, with 59.79% offering strep throat, 26.5% COVID-19 and 5.9% influenza POC tests. Active providers were more likely to agree or strongly agree to 26 out of 30 of the adapted DIBQ items, indicating that these were facilitators of implementation. The largest differences were in having the necessary resources (relative risk: 5.23; 95%CI: 3.34, 8.18), training (RR: 3.89; 95%CI: 2.57, 5.88) and knowing how (RR: 3.16; 95%CI: 2.33, 4.28) to deliver the service. In both groups, areas with low confidence were performing a focused physical assessment, analyzing rapid molecular tests and performing a nasal swab.

Conclusion

Community pharmacists in our sample commonly provide POC testing for Strep pharyngitis. Our results suggest organizational factors, skills, and knowledge were facilitators of service provision.
背景:艾伯塔省的社区药剂师有广泛的实践范围,可以对急性和慢性疾病进行护理点(POC)测试。然而,对呼吸道感染的POC检测的规定和药师的经验知之甚少。目的:探讨社区药师对急性上呼吸道感染(URTI)患者进行POC检测的类型、活跃和不活跃的URTI POC检测提供者在实施因素和置信度方面的差异,为急性上呼吸道感染(URTI)患者提供临床服务。方法:匿名、在线、横断面调查,于2024年2月向4035名在阿尔伯塔药学院注册的社区药剂师发送电子邮件邀请。该调查收集了人口统计数据和提供POC检测服务的信息。一个改编版的实施行为决定因素问卷(DIBQ)被用来确定障碍和促进因素。用单变量统计检验对数据进行描述性总结和组间比较。结果:最终分析共纳入370份应答者(应答率:9.2%,45% < 40岁,65%女性,28%农村,73%有额外处方授权)。大多数应答者(87%)对出现尿路感染症状的患者进行评估。四分之三(72.7%)提供POC检测,65%目前提供URTI POC检测,57.9%提供链球菌性咽喉炎检测,36.5%提供COVID-19检测,5.9%提供流感POC检测。积极的提供者更有可能同意或强烈同意30个经调整的DIBQ项目中的26个,这表明这些是实施的促进者。最大的差异是拥有必要的资源(相对风险:5.23;95%CI: 3.34, 8.18)、培训(相对危险度:3.89;95%CI: 2.57, 5.88)和知道如何提供服务(相对危险度:3.16;95%CI: 2.33, 4.28)。在这两组中,低可信度区域正在进行集中的物理评估,分析快速分子测试并进行鼻拭子。结论:本区社区药师普遍提供链球菌性咽炎POC检测。我们的研究结果表明,组织因素、技能和知识是服务提供的促进因素。
{"title":"Practices and implementation factors of point-of-care testing for acute upper respiratory tract infections by community pharmacists in Alberta: A cross-sectional survey","authors":"Omar E. Abdellatife,&nbsp;Scot H. Simpson,&nbsp;Theresa J. Schindel,&nbsp;Jody Shkrobot,&nbsp;Mark J. Makowsky","doi":"10.1016/j.japh.2025.102927","DOIUrl":"10.1016/j.japh.2025.102927","url":null,"abstract":"<div><h3>Background</h3><div>Community pharmacists in Alberta have a broad scope of practice and may conduct point-of-care (POC) tests for acute and chronic medical conditions. However, little is known about the provision and pharmacists' experiences in POC testing for respiratory infections.</div></div><div><h3>Objectives</h3><div>To explore the clinical services offered by community pharmacist to patients with acute upper respiratory tract infections (URTI) by describing the types of POC tests performed and differences in implementation factors and confidence between active and inactive URTI POC testing providers.</div></div><div><h3>Methods</h3><div>Anonymous, online, cross-sectional survey with email invitations sent to 4035 community pharmacists registered with the Alberta College of Pharmacy in February 2024. The survey collected information on demographics and provision of POC testing services. An adapted version of the Determinants of Implementation Behavior Questionnaire (DIBQ) was used to determine barriers and facilitators. The data were summarized descriptively and compared between groups using univariate statistical tests.</div></div><div><h3>Results</h3><div>A total of 370 responses were included in the final analysis (response rate: 9.2%, 45% &lt; 40 years old, 65% female, 28% rural, 73% have additional prescribing authorization). Most respondents (87%) provide assessments to patients presenting with URTI symptoms. Three quarters (72.7%) provide POC testing, 65% currently provide URTI POC tests, with 59.79% offering strep throat, 26.5% COVID-19 and 5.9% influenza POC tests. Active providers were more likely to agree or strongly agree to 26 out of 30 of the adapted DIBQ items, indicating that these were facilitators of implementation. The largest differences were in having the necessary resources (relative risk: 5.23; 95%CI: 3.34, 8.18), training (RR: 3.89; 95%CI: 2.57, 5.88) and knowing how (RR: 3.16; 95%CI: 2.33, 4.28) to deliver the service. In both groups, areas with low confidence were performing a focused physical assessment, analyzing rapid molecular tests and performing a nasal swab.</div></div><div><h3>Conclusion</h3><div>Community pharmacists in our sample commonly provide POC testing for Strep pharyngitis. Our results suggest organizational factors, skills, and knowledge were facilitators of service provision.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 1","pages":"Article 102927"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the American Pharmacists Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1